Beyond resistance: assessing sulbactam-Durlobactam’s role in Today’s clinical landscape

IF 4.2 2区医学 Q1 INFECTIOUS DISEASES Expert Review of Anti-infective Therapy Pub Date : 2024-05-02 DOI:10.1080/14787210.2024.2351026

Ahmad Z. Al Meslamani

引用次数: 0

Abstract

Published in Expert Review of Anti-infective Therapy (Just accepted, 2024)

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

超越耐药性：评估舒巴坦-杜鲁巴坦在当今临床中的作用

发表于《抗感染治疗专家评论》（刚被接受，2024 年）

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Expert Review of Anti-infective Therapy 医学-药学

CiteScore

11.20

自引率

0.00%

发文量

审稿时长

4-8 weeks

期刊介绍： Expert Review of Anti-Infective Therapy (ISSN 1478-7210) provides expert reviews on therapeutics and diagnostics in the treatment of infectious disease. Coverage includes antibiotics, drug resistance, drug therapy, infectious disease medicine, antibacterial, antimicrobial, antifungal and antiviral approaches, and diagnostic tests.

期刊最新文献

Could the next "disease X" be a pandemic of virus-induced encephalitis? What should our first medical response be? The opportunities and challenges of epigenetic approaches to manage herpes simplex infections. Potential activity of nanomaterials to combat SARS-CoV-2 and mucormycosis ‎coinfection‎. Clinical effectiveness of oral antivirals for non-hospitalized adult COVID-19 patients aged 18-60 years. Is self-medication with antibiotics among the public a global concern: a mixed-methods systematic review.